ATRA compensates for RIG‐I expression, thereby re‐triggering IFN response and potently inhibiting HMA‐resistant AML cell lines, xenograft mice, and patient‐derived primary cells. This evidence concerns the gene IFNA1 and acute myeloid leukemia.